<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <ArticleTitle>DARIDOREXANT: A DRUG TO TREAT INSOMNIA</ArticleTitle>
      <Abstract>In this review, we have explained the drug "Daridorexant" which is been used for the treatment of insomnia. Clinical research has shown, however, that individuals with insomnia have inconsistent reporting of subjective (i.e., self-reported diaries) and objective (i.e., PSG) estimations of their sleep characteristics. Daridorexant (QuviviqTM), an orally given dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA), for the treatment of insomnia. Daridorexant was chosen from a pool of medication candidates because it had an estimated effect duration of 8 hours at a dosage of 25 mg and a half-life designed to minimize residual effects that might impede daytime functioning. Symptoms have been self-reported by approximately 30% of the general population and can cause a wide range of daily impacts such as fatigue, decreased energy, mood changes, and cognitive impairments. We have explained the pharmacokinetics and pharmacodynamics profile of Daridorexant. It preferentially targets orexin neurons and inhibits downstream neuronal pathways that promote wakefulness; however, it does not affect neuronal pathways that induce adverse effects found with positive allosteric GABA-A receptor modulators. The possibility of biased signaling is being investigated in the context of arrestin-mediated pathways. The drugs used in the orexinergic system are also included in this review.</Abstract>
      <Keywords>Daridorexant, Insomnia, Allosteric GABA-A receptor modulators, Oxinergic system, Arrestin-mediated pathway.</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14855&amp;title=DARIDOREXANT: A DRUG TO TREAT INSOMNIA</Abstract>